Credit: Pixabay/CC0 Public Domain The cardiovascular safety of an interrupting beta-blocker could not be shown in comparison to continuation in patients with a history of myocardial infarction (MI) and there
Credit: Unsplash/CC0 Public Domain Vutrisiran significantly improved mortality, cardiovascular events and markers of disease progression in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM), according to late-breaking research presented in a
Summary of main findings by CNIC researchers. Clonal hematopoiesis and the expansion of blood cells carrying certain acquired mutations represent a new cause of atherosclerosis and cardiovascular disease, not a
A 3D image of an embryonic mouse heart. Endothelial cells vascularize the heart muscle walls (shown in green). This process establishes the coronary vasculature that nourishes the heart muscle. Credit:
Credit: CC0 Public Domain Research supported by the National Institutes of Health has found that measuring two types of fat in the bloodstream along with C-reactive protein (CRP), a marker
Credit: Unsplash/CC0 Public Domain Patients with heart failure, a condition affecting more than 60 million worldwide, are four times more likely to receive the optimal combination of medications after 12
Credit: Pixabay/CC0 Public Domain New research shows that a treatment plan based on a novel combination of low doses of three anti-hypertensive drugs in a single pill—known as GMRx2—was superior
